FDAnews
www.fdanews.com/articles/108370-phase-iib-pancreatic-cancer-trial-commences-for-psivida-product

Phase IIb Pancreatic Cancer Trial Commences for pSivida Product

July 8, 2008

A potential new brachytherapy treatment for inoperable pancreatic cancer is being studied in pSivida’s newly initiated Phase IIb clinical trial.

BrachySil is a combination of BioSilicon, a proprietary porous silicon, and the isotope phosphorus, a proven anti-cancer therapeutic. It can be delivered by endoscopic ultrasound, the company said.

The study will determine the safety of escalating radiation doses of the product.